Probiotec Limited develops, manufactures, and sells pharmaceutical, consumer health, and nutraceutical products in Australia and internationally. The company operates in three segments: Branded Pharmaceuticals, Contract Manufacture, and Obesity and Weight Management. It primarily engages in the contract manufacturing of pharmaceutical, food, and animal nutrition products for pharmaceutical and food companies; manufacture and sale of a range of obesity and weight management products in various channels, including FMCG, pharmacy, health food stores, and online; and provision of Celebrity Slim and Impromy weight loss programs. The company also provides owned and licensed branded pharmaceutical products, over-the-counter pharmaceutical products, complementary medicines, and specialty ingredients. Probiotec Limited was founded in 1997 and is based in Laverton North, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9278 7555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$85.28 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Probiotec (ASX:PBP) Frequently Asked Questions
What is Probiotec's stock symbol?
Probiotec trades on the ASX under the ticker symbol "PBP."
How often does Probiotec pay dividends? What is the dividend yield for Probiotec?
Probiotec announced a Interim dividend on Wednesday, February 27th. Shareholders of record on Tuesday, March 19th will be paid a dividend of 0.01 per share on Tuesday, March 19th. This represents a dividend yield of 0.67%. The ex-dividend date is Friday, March 1st. View Probiotec's Dividend History.
Has Probiotec been receiving favorable news coverage?
Headlines about PBP stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Probiotec earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Probiotec.
Who are some of Probiotec's key competitors?
Some companies that are related to Probiotec include CannTrust (TRST), ESSA Pharma (EPI), Flowr (FLWR), Benchmark (BMK), ICC Labs (ICC), Shield Therapeutics (STX), WeedMD (WMD), Althea Group (AGH), Harvest One Cannabis (HVT), Auscann Group (AC8), Eve & Co Inc (EVE), Depomed (ASRT), Delta 9 Cannabis (NINE), Biosyent (RX) and Invion (IVX).
Who are Probiotec's key executives?
Probiotec's management team includes the folowing people:
- Mr. Wesley Stringer B.Comm, LLB (Hons), CPA, CEO, MD & Exec. Director
- Mr. Jared Stringer, CFO, Company Sec. & Financial Controller
- Ms. Julie McIntosh, Chief Operating Officer
- Mr. Alan Hong, Gen. Mang. of Accounting
- Mr. Dustin Stringer, Gen. Mang. of Marketing
How big of a company is Probiotec?
What is Probiotec's official website?
How can I contact Probiotec?
The company can be reached via phone at 61 3 9278 7555.
MarketBeat Community Rating for Probiotec (ASX PBP)
MarketBeat's community ratings are surveys of what our community members think about Probiotec and other stocks. Vote "Outperform" if you believe PBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
